These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 9845798)
1. Formulation of a protein with propellant HFA 134a for aerosol delivery. Williams RO; Liu J Eur J Pharm Sci; 1999 Jan; 7(2):137-44. PubMed ID: 9845798 [TBL] [Abstract][Full Text] [Related]
2. Tetrafluoroethane (HFC 134A) propellant-driven aerosols of proteins. Brown AR; George DW Pharm Res; 1997 Nov; 14(11):1542-7. PubMed ID: 9434272 [TBL] [Abstract][Full Text] [Related]
3. Influence of propellant composition on drug delivery from a pressurized metered-dose inhaler. Williams RO; Repka M; Liu J Drug Dev Ind Pharm; 1998 Aug; 24(8):763-70. PubMed ID: 9876524 [TBL] [Abstract][Full Text] [Related]
4. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. Donnell D; Harrison LI; Ward S; Klinger NM; Ekholm BP; Cooper KM; Porietis I; McEwen J Eur J Clin Pharmacol; 1995; 48(6):473-7. PubMed ID: 8582466 [TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. Ayres JG; Millar AB; Sykes AP Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685 [TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Cripps A; Riebe M; Schulze M; Woodhouse R Respir Med; 2000 Jun; 94 Suppl B():S3-9. PubMed ID: 10919679 [TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Fireman P; Prenner BM; Vincken W; Demedts M; Mol SJ; Cohen RM Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808 [TBL] [Abstract][Full Text] [Related]
12. Plume temperature emitted from metered dose inhalers. Brambilla G; Church T; Lewis D; Meakin B Int J Pharm; 2011 Feb; 405(1-2):9-15. PubMed ID: 21129465 [TBL] [Abstract][Full Text] [Related]
13. Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI. Williams RO; Patel AM; Barron MK; Rogers TL Drug Dev Ind Pharm; 2001 May; 27(5):401-12. PubMed ID: 11448047 [TBL] [Abstract][Full Text] [Related]
14. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. Cheng YS; Fu CS; Yazzie D; Zhou Y J Aerosol Med; 2001; 14(2):255-66. PubMed ID: 11681657 [TBL] [Abstract][Full Text] [Related]
15. The effect of reduction of propellant mass fraction on the injection profile of metered dose inhalers. Ju D; Shrimpton J; Hearn A Int J Pharm; 2010 May; 391(1-2):221-9. PubMed ID: 20227471 [TBL] [Abstract][Full Text] [Related]
18. Formulation and evaluation of novel reverse microemulsions containing salmon calcitonin in hydrofluoroalkane propellants. Shan Z; Tan Y; Qin L; Li G; Pan X; Wang Z; Yu X; Wang Q; Wu C Int J Pharm; 2014 May; 466(1-2):390-9. PubMed ID: 24657140 [TBL] [Abstract][Full Text] [Related]